Special Issue

Current Advances in T-cell-Based Cancer Immunotherapy

Message from the Guest Editors

The development of immune checkpoint inhibitors revolutionized cancer treatments in the early 2010s. Whereas the introduction of the immune checkpoint inhibitors opened the new era of cancer therapy, their efficacy is not yet satisfactory. It is thus imperative to further develop T-cell-based immunotherapies, including the adoptive transfer of cytotoxic □□ T cells, chimeric antigen receptor T cells, and □□ T cells. In order to improve the efficacy of such T-cell-based cancer treatments, it is essential to delineate the precise mechanism underlying the effect of cultured or genetically-engineered T cells on tumor cells. This Special Issue of Cells is for contributions on all cytobiological aspects related to T-cell-based immunotherapies. You are invited to submit your contributions in the form of original research articles, reviews, or shorter perspective articles. Relevant observations made at the cellular level could come from the following areas: T-cell-based cancer immunotherapy □□ T cells CAR-T cells immune checkpoint inhibitors combination therapy

Guest Editors

Prof. Dr. Yoshimasa Tanaka

Center for Medical Innovation, Nagasaki University, Nagasaki 852-8588, Japan

Prof. Dr. Craig T. Morita

Carver College of Medicine, University of Iowa, Iowa City, Johnson County, IA 52242, USA

Deadline for manuscript submissions

closed (30 September 2021)

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/si/52712

Cells
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cells@mdpi.com

mdpi.com/journal/cells

Cells

an Open Access Journal by MDPI

Impact Factor 5.2
CiteScore 10.5
Indexed in PubMed

mdpi.com/journal/cells

About the Journal

Message from the Editorial Board

Cells has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

Editors-in-Chief

Dr. Alexander E. Kalyuzhny
Dental Basic Sciences, University of Minnesota, 308 Harvard St. SE, Minneapolis, MN 55455, USA

Prof. Dr. Cord Brakebusch
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Cell Biology) / CiteScore - Q1 (General Biochemistry, Genetics and Molecular Biology)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).